Investing Featured

America's Pharmacy Closures Are a Merger Nobody Approved

When a drugstore dies, its prescriptions flow overwhelmingly to chains owned by the middlemen who set pharmacy reimbursement rates. CVS just booked a record quarter on the redistribution — and February's reform law arrived after the consolidation it was meant to prevent.

Alpha One

06 Aug 2026 • 7 min read

On Tuesday morning, CVS Health reported one of the strongest quarters in its history. Revenue hit $106.1 billion, up 7.3% year over year. Adjusted earnings per share came in at $2.58, up from $1.81. Management raised full-year guidance by sixty cents. The stock has been one of the best performers in the Dow this year.

Buried on page five of the release is the sentence that explains where a meaningful part of that strength came from. Prescriptions filled rose 4.3% in the quarter, "primarily driven by incremental volume resulting from the Company's Rite Aid prescription file acquisitions."

Rite Aid no longer exists. It filed for bankruptcy twice, liquidated in 2025, and closed or sold every one of its roughly 1,200 remaining drugstores. CVS bought prescription files and select assets out of the wreckage, a transaction it completed in the third quarter of last year. Those files — the medication histories of millions of former Rite Aid customers — are now filling CVS pharmacies' script counters and CVS's earnings guidance.

Nobody merged CVS and Rite Aid. No regulator reviewed the combination of their customer bases. The market did it through the side door: one chain collapsed, and its patients were redistributed. That redistribution is the most underexamined force in American healthcare right now — because it is happening everywhere, continuously, one closed drugstore at a time.

Where prescriptions go when a pharmacy dies

A study published in JAMA Health Forum last month tracked exactly what happened to patients when 955 Rite Aid pharmacies closed. The findings, summarized by Drug Topics, are stark:

96.4% of prescriptions transferred to major chains — not to independent pharmacies, not to grocers, but to the largest surviving players.
68.7% went to pharmacies affiliated with a pharmacy benefit manager (PBM) — meaning the prescription ended up inside one of the vertically integrated giants that also control drug reimbursement.
In minority-majority counties, transfers of more than 15 miles were twelve times more common than elsewhere. In low-density areas, nearly 17% of transfers moved patients to a pharmacy with no nearby bus stop.

Read that middle number again. When a pharmacy dies in America, more than two-thirds of its business flows to a chain owned by the same class of companies that set the reimbursement rates pharmacies live or die on. The referee's team keeps winning, and the losing teams' fans are required to switch jerseys.

Briefings like this land in members' inboxes before the market prices them in. Join free →

The math that kills the corner drugstore

Why don't independent pharmacies pick up the displaced volume? The JAMA Health Forum researchers found they often can't afford to. Under prevailing PBM contracts, reimbursement on many prescriptions sits at or below the pharmacy's acquisition cost once fees are extracted — which means a sudden influx of transferred prescriptions can be cash-flow negative. The dying pharmacy's customers are, financially speaking, a burden the independent down the street cannot take on. The chains owned by PBMs have no such problem, because they are paid by themselves.

The scale of that gatekeeping power is documented. The Federal Trade Commission's staff report on pharmacy benefit managers found that the three largest PBMs — CVS Caremark, Express Scripts, and Optum Rx, owned respectively by CVS, Cigna, and UnitedHealth — processed roughly 80% of the 6.6 billion prescriptions dispensed in the United States. The same report found specialty generic drugs marked up by hundreds or thousands of percent when dispensed through PBM-affiliated pharmacies. CVS's own PBM covers approximately 87 million plan members. Its retail arm operates roughly 9,000 pharmacies. It is the rate-setter, the payer, and the dispenser in one corporate body.

The reimbursement squeeze is not a talking point — it is the stated reason the store base is shrinking. Walgreens, now private under Sycamore Partners, announced plans in late 2024 to close roughly 1,200 stores over three years and shuttered about 500 in fiscal 2025 alone. Roughly three-quarters of a drugstore's revenue comes from the pharmacy counter, and as one analyst put it, stores close "because prescription volume at that address can't cover the rent under current reimbursement math." For decades, generous generic dispensing margins subsidized the convenience of the corner drugstore. The middlemen compressed the margin; delivery apps commoditized the convenience. The corner drugstore's economic reason to exist evaporated.

Even CVS — the biggest beneficiary of the shakeout — listed "pharmacy reimbursement pressure" among its retail segment headwinds this week. The largest PBM owner in America is citing pressure from PBM reimbursement. That is not irony. That is a flywheel.

Forty-eight million Americans in the desert

The cumulative result now has a map. On July 31, the National Community Pharmacists Association and the University of Southern California launched an interactive pharmacy-desert mapping tool showing that one in eight American neighborhoods lacks convenient access to a pharmacy. Roughly 48 million Americans live in a pharmacy desert — more than a mile from a drugstore in urban areas, more than ten miles in rural ones. In Connecticut, hardly frontier country, more than 17% of residents now qualify.

This matters beyond inconvenience. Boston University researchers have documented that closures concentrate in Black and Latino neighborhoods and correlate with measurably worse medication adherence — for statins, blood pressure drugs, insulin. Skipped maintenance medication becomes emergency-room volume. The cost doesn't disappear when the drugstore does; it migrates to the most expensive setting in the system.

The law that arrived after the heist

Washington noticed. The Consolidated Appropriations Act of 2026, signed on February 3, contains the most sweeping PBM reform ever enacted: 100% of manufacturer rebates must be passed through to health plans, PBM compensation is "delinked" from drug list prices, DIR clawback fees are banned, and a new "Essential Retail Pharmacy" designation prohibits PBMs from reimbursing the last independent pharmacy in an area less than they pay their own affiliated stores. Civil penalties run to $10,000 per day. Starting in 2028, Medicare drug plans must admit any pharmacy willing to meet standard terms into their networks.

It is a serious law. It is also late. The concentration it targets has already happened. Rite Aid's customer base was redistributed before the ink dried. The any-willing-pharmacy provision arrives in 2028 — useful only to pharmacies still alive to be willing. A protected reimbursement floor cannot resurrect the 955 storefronts in the JAMA study, and prescription files, once transferred, rarely transfer back. The reform bill is a fence built around an empty pasture.

What it means for money

The vertically integrated players won the land grab, but now own the regulatory bullseye. CVS's quarter shows the near-term math: absorbed scripts are accretive, and the retail segment grew operating income 10% while the store base shrank. UnitedHealth's Optum Rx and Cigna's Express Scripts ran the same playbook. But the CAA's delinking and pass-through provisions take direct aim at how these businesses monetize, and FTC enforcement pressure has not relaxed with the change in the pharmacy landscape. The rerating question for all three is whether dispensing-volume gains outrun regulated-margin losses.

The Essential Retail Pharmacy floor is a quiet tailwind for the independents' suppliers. If the reimbursement floor stabilizes rural independents, the beneficiaries are the wholesalers who supply them — McKesson, Cencora, and Cardinal Health — whose independent-pharmacy customer books were in structural runoff.

The desert is a market. Amazon Pharmacy is expanding same-day delivery into exactly the geographies the chains are abandoning, capturing displaced prescriptions without paying rent on a single corner. Mark Cuban's Cost Plus Drugs and the cash-pay channel grow every time an insured patient's local option disappears. The pharmacy counter is following the video store: the physical footprint shrinks, and the economics reconstitute around logistics.

The bottom line: America's drugstore die-off is not a retail story. It is an unreviewed consolidation of drug access into the hands of the companies that control drug reimbursement — executed not through mergers regulators could block, but through closures no one could stop. CVS's record quarter is the first clean read on what that consolidation earns. The February reform law will shape who profits from the next phase. It cannot un-happen the last one.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. Free members get the daily brief in their inbox; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.